Marketing Surveillance and Pharmacovigilance: QA's Role in Ensuring Product Safety

Post-marketing safety of pharmaceutical products is a critical aspect of public health, requiring the integration of marketing surveillance, pharmacovigilance, and quality assurance (QA). Marketing surveillance ensures that medicines in the market meet established quality standards, comply with regulatory requirements, and remain free from defects throughout distribution. Pharmacovigilance complements this by continuously monitoring, detecting, assessing, and preventing adverse drug reactions, thereby maintaining a favorable benefit–risk profile over the product’s lifecycle. QA serves as the backbone of these processes, enforcing standard operating procedures, conducting audits, maintaining data integrity, and implementing corrective and preventive actions to uphold product safety. Historical incidents, such as the thalidomide tragedy, highlight the consequences of inadequate oversight, reinforcing the importance of robust QA systems. With the advent of advanced data analytics, artificial intelligence, and global regulatory collaboration, modern pharmaceutical safety monitoring has become more proactive and efficient. However, challenges such as fragmented reporting systems, regulatory complexity, and resource limitations remain. A well-coordinated, quality-driven approach that harmonizes marketing surveillance and pharmacovigilance ensures that pharmaceutical products are consistently safe, effective, and reliable for patients worldwide.